Welcome to our dedicated page for Ibio SEC filings (Ticker: IBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iBio, Inc. filings document material events for an AI-driven biotechnology company developing precision antibody therapies. Recent Form 8-K disclosures cover clinical and regulatory updates for IBIO-600, preclinical data for IBIO-610, quarterly financial results, Regulation FD communications and other pipeline-related events.
The company's filings also record capital-structure matters involving common stock, pre-funded warrants and Series G warrants, along with shareholder voting results, board composition, committee appointments and governance items disclosed through annual-meeting and material-event reports.
iBio, Inc. director Elizabeth Stoner received a grant of stock options covering 60,000 shares of common stock. The options have an exercise price of 1.42 per share and expire on 2036-05-17. They vest monthly on a pro rata basis over 36 months, and following this award she holds 60,000 options in total.
iBio, Inc. reporting persons led by Logos Global Management state they beneficially own 0 shares of Common Stock and report 0% ownership. The filing lists Logos Global, Logos Global GP, Logos Global Master Fund, Logos GP and Arsani William and disclaims group membership. The reporting persons certified the holdings and signed the amendment on 05/15/2026.
iBio, Inc. amendment to a Schedule 13G/A reports that Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen each beneficially owned 0% of iBio common stock as of the close of business on 03/31/2026. The filing lists the reporting persons' registered business address and CUSIP 451033708, and is signed by an authorized person on 05/15/2026.
iBio, Inc. Schedule 13G/A shows EcoR1 Capital, LLC and related reporting persons beneficially own 1,583,000 shares of Common Stock, representing 4.6% of the class. The filing states the calculation is based on 34,543,561 shares outstanding as of February 9, 2026.
The filing lists shared voting and dispositive power for the reported positions and clarifies EcoR1 is the general partner of the funds while Oleg Nodelman is the control person. Signatures show the filing was executed on May 14, 2026.
iBio, Inc. ownership update: Cormorant Asset Management and Bihua Chen report beneficial ownership of 3,834,335 shares of common stock, representing 9.99% of the class. The holdings reflect shares issuable upon exercise of pre-funded and Series G warrants, subject to a 9.99% beneficial ownership limit. The filing cites 34,543,561 shares outstanding as of February 9, 2026. The Reporting Persons note up to 7,752,005 shares would be issuable upon exercise of the Warrants absent the ownership limitation; 3,570,000 Series H shares are excluded from the reported total.
iBio, Inc. Schedule 13G: Sirenia Capital Management and Alex Silverstein report beneficial ownership of 11,586,340 shares of Common Stock, representing 9.9% of the class based on 34,543,561 shares outstanding as of February 24, 2026.
The cover disclosure states the count includes 10,710,000 shares issuable upon exercise of warrants held by a managed account but notes those warrants are subject to a 9.99% Blocker, which caps exercise so the Reporting Persons cannot exercise to exceed 9.99%.
iBio, Inc. filed an initial ownership report for director Elizabeth Stoner on Form 3. This filing establishes her status as a board member under SEC reporting rules but does not list any stock or option transactions. It is an administrative disclosure that begins her ongoing insider reporting obligations.
iBio reports beneficial ownership disclosure by Affinity Asset Advisors, LLC and Michael Cho. The Reporting Persons state they beneficially own 3,489,048 shares of common stock, representing approximately 9.99% of the outstanding common stock as of March 31, 2026. This amount includes 381,848 shares issuable upon exercise of warrants subject to a 9.99% Beneficial Ownership Limitation.
The filing ties the percentage to a total share base of 34,925,409 shares outstanding as of the stated date and attributes sole voting and dispositive power over the disclosed shares to the Adviser and Mr. Cho.
iBio, Inc. ownership update: Frazier Life Sciences Public Fund, L.P. reports 1,953,467 shares of Common Stock, representing 5.7% of the class based on February 9, 2026 outstanding shares. The filing states certain Pre-Funded Warrants held by affiliated funds could purchase 7,557,258, 70,668, and 886,335 shares respectively, each exercisable subject to a 9.99% beneficial ownership limit.
The reporting group clarifies governance and attribution: FHMLSP, L.P. is GP of the public fund and FHMLSP, L.L.C. manages the GP via an investment committee; several affiliated funds report 0 shares held. Signatures from the reporting persons are dated May 12, 2026.
iBio, Inc. reported no revenue for the quarter ended March 31, 2026 and a net loss of $7.7M, widening from $4.9M a year earlier, as it continues to invest in obesity and cardiometabolic antibody programs.
For the nine months, the net loss was $22.4M versus $13.2M in the prior-year period, driven by higher research and development and general and administrative expenses plus a $5.0M impairment of an oncology intangible asset. Operating cash outflow was $17.0M.
Liquidity strengthened significantly: cash and cash equivalents were $47.6M and investments in debt securities were $27.2M, for total liquid financial assets of about $74.8M. This reflects an underwritten public offering of approximately $50M, a private placement of approximately $26M, and about $13.8M of warrant exercise proceeds during the period, plus additional warrant exercises after quarter-end. The company now believes this cash is sufficient to fund operations for at least 12 months from the financial statement issuance date.
iBio remains a preclinical-stage biotechnology company using its AI Drug Discovery Platform to develop precision antibodies, with lead obesity-related candidates IBIO-600 and IBIO-610 expected to enter first-in-human trials in calendar 2026 and the first half of 2027, respectively.